Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Autor: Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Mortier, Laurent, Dereure, Olivier, Lebbe, Céleste, Mansard, Sandrine, Grange, Florent, Neidhardt, Eve-Marie, Lesimple, Thierry, Machet, Laurent, Bedane, Christophe, Maillard, Hervé, Dalac-Rat, Sophie, Nardin, Charlée, Szenik, Alexandra, Denden, Amine, Dutriaux, Caroline

Publikováno v: In European Journal of Cancer September 2021 154:57-65

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases

Autor: Caroline Dutriaux, Caroline Robert, Jean-Jacques Grob, Laurent Mortier, Olivier Dereure, Céleste Lebbe, Sandrine Mansard, Florent Grange, Eve-Marie Neidhardt, Thierry Lesimple, Laurent Machet, Christophe Bedane, Hervé Maillard, Sophie Dalac-Rat, Charlée Nardin, Alexandra Szenik, Amine Denden, Philippe Saiag

Publikováno v: European journal of cancer (Oxford, England : 1990). 175

Despite the poor prognosis associated with melanoma brain metastases (BM), data concerning these patients and their inclusion in clinical trials remains scarce. We report here the efficacy results of a subgroup analysis in patients with BRAFV600-muta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be0430ac962fb3d47fd679c1d6bc0494
https://pubmed.ncbi.nlm.nih.gov/36170791

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Autor: Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob

Publikováno v: European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩

International audience; Background: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM). In a la

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2
https://hal.science/hal-03401780

Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

Autor: S. Dalac-Rat, P. Saiag, C. Robert, Christophe Bedane, Olivier Dereure, C. Lebbé, A. Denden, C. Nardin, Thierry Lesimple, Sandrine Mansard, H. Maillard, Florent Grange, A. Szenik, J.-J. Grob, C. Dutriaux, E.-M. Neidhardt, Laurent Machet, L. Mortier

Publikováno v: Annals of Oncology. 30:v546

Background BRAF and MEK inhibitors dabrafenib (D) and trametinib (T) have transformed BRAFV600-mutant melanoma patients’ (pts) treatment. In a large prospective trial of pts treated with combination D+T, which also included pts with brain metastasi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::94103628279d8ee700e1a1ed9b3859aa
https://doi.org/10.1093/annonc/mdz255.027

1338P - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

Autor: Saiag, P. ¹, Robert, C. ², Grob, J.J. ³, Mortier, L. ⁴, Dereure, O. ⁵, Lebbe, C. ⁶, Mansard, S. ⁷, Grange, F. ⁸, Neidhardt, E.-M. ⁹, Lesimple, T. ¹⁰, Machet, L. ¹¹, Bedane, C. ¹², Maillard, H. ¹³, Dalac-Rat, S. ¹⁴, Nardin, C. ¹⁵, Szenik, A. ¹⁶, Denden, A. ¹⁷, Dutriaux, C. ¹⁸

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v546-v546